Bristol-Myers Squibb's Daklinza Gets EU Nod

Friday, October 3, 2014

Source: FDA News

Bristol-Myers Squibb says it will soon start marketing its hepatitis C drug Daklinza in the European Union, following its approval last week.
Daklinza (daclatasvir) is indicated for use in conjunction with other therapies, such as Gilead Sciences' blockbuster drug Sovaldi (sofosbuvir).

View All News »